Bionik Laboratories Corp.
BNKLDelisted- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- SEC CIK
- 0001508381
Bionik Laboratories Corp. was delisted in 2023; its insiders filed their last Form 4 on Jun 21, 2023; no institution reported holding it in 13F filings for Q4 2022; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Bionik Laboratories Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Bionik Laboratories Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gaston-Dreyfus Remi | Director, 10% Owner | 4,917,749Indirect | Jun 21, 2023 | 0 |
| Auberton-Herve Andre-Jacques | Director | 1,109,271Indirect | Jun 21, 2023 | 0 |
| Matine Charles | Director | 206,985 | Jun 21, 2023 | 0 |
| Russo Richard Paul Jr | CEO and President | – | Oct 13, 2022 | 0 |
| Wass Loren W. | See Remarks | – | Oct 18, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 21, 2023 (view filing) | Jun 13 | 8 daysLate | Auberton-Herve Andre-JacquesDirector | PPurchaseCommon Stock, par value $0.001 per share | +366.7K | $0.60 | +$220.0K | –1 after | DerivativePrice outlier |
| Jun 21, 2023 (view filing) | Jun 9 | 12 daysLate | Matine CharlesDirector | PPurchaseCommon Stock, par value $0.001 per share | +180.6K | $0.60 | +$108.3K | +683.1%207.0K after | |
| Jun 21, 2023 (view filing) | Jun 9 | 12 daysLate | Gaston-Dreyfus RemiDirector, 10% Owner | PPurchaseCommon Stock, par value $0.001 per share | +180.6K | $0.60 | +$108.3K | +11.0%1.81M after | |
| Jun 21, 2023 (view filing) | Jun 9 | 12 daysLate | Auberton-Herve Andre-JacquesDirector | PPurchase | +650.0K | $0.60 | +$390.0K | +238.0%923.2K after | |
| Dec 13, 2021 (view filing) | Mar 26 | 262 daysLate | Gaston-Dreyfus RemiDirector, 10% Owner | PPurchaseCommon Stock, par value $0.001 per share | +135.6K | – | – | +10.6%1.42M after |